Justin Knox1, Melanie Wall1, Katie Witkiewitz2, Henry R Kranzler3, Daniel E Falk4, Raye Litten4, Karl Mann5, Stephanie S O'Malley6, Jennifer Scodes7, Raymond Anton8, Deborah S Hasin9. 1. Columbia University Mailman School of Public Health, 722 West 168th Street, New York, NY, 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA. 2. Department of Psychology, University of New Mexico, 1 University of New Mexico, Albuquerque, NM, 87131, USA. 3. Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market Street, Philadelphia, PA, 19104, USA; Crescenz Veterans Affairs Medical Center, 3900 Woodland Avenue, Philadelphia, PA, 19104, USA. 4. National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892, USA. 5. Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, J 5, 68159, Mannheim, Germany. 6. Department of Psychiatry, Yale School of Medicine, 300 George Street, New Haven, CT, 06511, USA. 7. New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA. 8. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC, 29425, USA. 9. Columbia University Mailman School of Public Health, 722 West 168th Street, New York, NY, 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA. Electronic address: dsh2@columbia.edu.
Abstract
BACKGROUND: To provide information on the clinical relevance of a reduction in the World Health Organization (WHO) drinking risk categories, we examined their relationship to an important indicator of how individuals feel and function: drug use disorders (DUDs), i.e., those involving substances other than alcohol. METHOD: Current drinkers in a U.S. national survey (n = 22,005) were interviewed in 2001-02 and re-interviewed 3 years later. WHO drinking risk levels and DSM-IV-defined DUD were assessed at both waves. The relationship of changes in WHO drinking risk levels to the presence of DUD were examined using adjusted odds ratios (aOR). RESULTS: At Wave 1, 2.5% of respondents were WHO very-high-risk drinkers, and 2.5%, 4.8%, and 90.2% were high-risk, moderate-risk, and low-risk drinkers, respectively. Among Wave 1 very-high-risk drinkers, significantly lower odds of DUD at Wave 2 were predicted by reductions in WHO risk levels of one, two or three levels (aOR = 0.15, 0.01, 0.24, respectively; all p-values <.0001). Among participants who initially were drinking at lower risk levels, reductions in drinking or abstinence were generally associated with significantly lower odds of DUD, although the results were less consistent. CONCLUSIONS: Among very-high-risk drinkers, reduction in the WHO drinking risk categories were associated with lower risk of a DUD. These results add to findings indicating that reductions in WHO drinking risk levels are a meaningful indicator of how individuals feel and function and could therefore serve as informative outcomes in alcohol clinical trials. WHO risk levels can also guide treatment goals and clinical recommendations on drinking reduction.
BACKGROUND: To provide information on the clinical relevance of a reduction in the World Health Organization (WHO) drinking risk categories, we examined their relationship to an important indicator of how individuals feel and function: drug use disorders (DUDs), i.e., those involving substances other than alcohol. METHOD: Current drinkers in a U.S. national survey (n = 22,005) were interviewed in 2001-02 and re-interviewed 3 years later. WHO drinking risk levels and DSM-IV-defined DUD were assessed at both waves. The relationship of changes in WHO drinking risk levels to the presence of DUD were examined using adjusted odds ratios (aOR). RESULTS: At Wave 1, 2.5% of respondents were WHO very-high-risk drinkers, and 2.5%, 4.8%, and 90.2% were high-risk, moderate-risk, and low-risk drinkers, respectively. Among Wave 1 very-high-risk drinkers, significantly lower odds of DUD at Wave 2 were predicted by reductions in WHO risk levels of one, two or three levels (aOR = 0.15, 0.01, 0.24, respectively; all p-values <.0001). Among participants who initially were drinking at lower risk levels, reductions in drinking or abstinence were generally associated with significantly lower odds of DUD, although the results were less consistent. CONCLUSIONS: Among very-high-risk drinkers, reduction in the WHO drinking risk categories were associated with lower risk of a DUD. These results add to findings indicating that reductions in WHO drinking risk levels are a meaningful indicator of how individuals feel and function and could therefore serve as informative outcomes in alcohol clinical trials. WHO risk levels can also guide treatment goals and clinical recommendations on drinking reduction.
Authors: Katie Witkiewitz; Adam D Wilson; Matthew R Pearson; Kevin A Hallgren; Daniel E Falk; Raye Z Litten; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Stephanie S O'Malley; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2017-04-05 Impact factor: 3.455
Authors: Bridget F Grant; S Patricia Chou; Tulshi D Saha; Roger P Pickering; Bradley T Kerridge; W June Ruan; Boji Huang; Jeesun Jung; Haitao Zhang; Amy Fan; Deborah S Hasin Journal: JAMA Psychiatry Date: 2017-09-01 Impact factor: 21.596
Authors: Katie Witkiewitz; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Corey R Roos; Megan Kirouac; Adam D Wilson; Kevin S Montes; Nick Heather Journal: Addiction Date: 2017-06-26 Impact factor: 6.526
Authors: B F Grant; R B Goldstein; S P Chou; B Huang; F S Stinson; D A Dawson; T D Saha; S M Smith; A J Pulay; R P Pickering; W J Ruan; W M Compton Journal: Mol Psychiatry Date: 2008-04-22 Impact factor: 15.992
Authors: Matthew K Nock; Guilherme Borges; Evelyn J Bromet; Jordi Alonso; Matthias Angermeyer; Annette Beautrais; Ronny Bruffaerts; Wai Tat Chiu; Giovanni de Girolamo; Semyon Gluzman; Ron de Graaf; Oye Gureje; Josep Maria Haro; Yueqin Huang; Elie Karam; Ronald C Kessler; Jean Pierre Lepine; Daphna Levinson; Maria Elena Medina-Mora; Yutaka Ono; José Posada-Villa; David Williams Journal: Br J Psychiatry Date: 2008-02 Impact factor: 9.319
Authors: Katie Witkiewitz; Nick Heather; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Henry R Kranzler; Karl F Mann; Stephanie S O'Malley; Raymond F Anton Journal: Addiction Date: 2020-03-10 Impact factor: 6.526
Authors: Justin Knox; Jennifer Scodes; Katie Witkiewitz; Henry R Kranzler; Karl Mann; Stephanie S O'Malley; Melanie Wall; Raymond Anton; Deborah S Hasin Journal: Alcohol Clin Exp Res Date: 2020-07-03 Impact factor: 3.455
Authors: Deborah S Hasin; Efrat Aharonovich; Barry S Zingman; Malka Stohl; Claire Walsh; Jennifer C Elliott; David S Fink; Justin Knox; Sean Durant; Raquel Menchaca; Anjali Sharma Journal: J Subst Abuse Treat Date: 2022-01-31
Authors: Arnie P Aldridge; Gary A Zarkin; William N Dowd; Katie Witkiewitz; Deborah S Hasin; Stephanie S O'Malley; Keith Isenberg; Raymond F Anton Journal: J Addict Med Date: 2021-12-03 Impact factor: 4.647
Authors: Corey R Roos; Charla Nich; Chung Jung Mun; Theresa A Babuscio; Justin Mendonca; André Q C Miguel; Elise E DeVito; Sarah W Yip; Katie Witkiewitz; Kathleen M Carroll; Brian D Kiluk Journal: Drug Alcohol Depend Date: 2019-10-21 Impact factor: 4.492
Authors: Dvora Shmulewitz; Efrat Aharonovich; Katie Witkiewitz; Raymond F Anton; Henry R Kranzler; Jennifer Scodes; Karl F Mann; Melanie M Wall; Deborah Hasin Journal: Am J Psychiatry Date: 2021-01-21 Impact factor: 19.242
Authors: Emily E Hartwell; Richard Feinn; Katie Witkiewitz; Timothy Pond; Henry R Kranzler Journal: Alcohol Clin Exp Res Date: 2021-07-05 Impact factor: 3.928